Thermo Fisher Scientific Inc. (TMO) said the company's offer to acquire all of the ordinary shares of QIAGEN N.V. (QGEN) has lapsed as the minimum acceptance threshold condition to the offer has not been satisfied. Thermo Fisher has terminated the acquisition deal with QIAGEN, and QIAGEN will pay to Thermo Fisher an expense reimbursement payment of $95 million in cash.

Create Account

Dark

chart

exchange

RTTNews | Aug 13, 2020 07:42AM EDT

07:41 Thursday, August 13, 2020 (RTTNews.com) - Thermo Fisher Scientific Inc. (TMO) said the company's offer to acquire all of the ordinary shares of QIAGEN N.V. (QGEN) has lapsed as the minimum acceptance threshold condition to the offer has not been satisfied. Thermo Fisher has terminated the acquisition deal with QIAGEN, and QIAGEN will pay to Thermo Fisher an expense reimbursement payment of $95 million in cash.

By the end of the acceptance period on August 10, 2020, a total of 107,546,187 QIAGEN shares, representing 47.02% of the issued and outstanding ordinary shares of QIAGEN, were validly tendered into the offer.

Read the original article on RTTNews ( https://www.rttnews.com/3121195/thermo-fisher-terminates-merger-deal-with-qiagen-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved